Comparative Pharmacology
Head-to-head clinical analysis: OXSORALEN ULTRA versus TRISORALEN.
Peer-Reviewed Evidence
Head-to-head clinical analysis: OXSORALEN ULTRA versus TRISORALEN.
OXSORALEN-ULTRA vs TRISORALEN
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Oxsoralen-Ultra (methoxsalen) is a psoralen derivative that, upon photoactivation by UVA radiation, forms covalent cross-links with DNA, thereby inhibiting DNA synthesis and cell division. It also suppresses cutaneous immune responses and reduces epidermal cell turnover.
Psoralen (trisoralen) intercalates into DNA and, upon UVA irradiation, forms covalent cross-links between pyrimidine bases, inhibiting DNA replication and cell division. It also suppresses DNA synthesis and epidermal cell proliferation.
0.6 mg/kg orally as a single dose 2 hours prior to PUVA therapy, administered 3 times per week on non-consecutive days.
10-70 mg orally 2 hours before UVA exposure, given 2-3 times per week, with dose based on body weight (0.6 mg/kg).
None Documented
None Documented
2 hours (terminal) with clinical context: elimination is rapid; no accumulation with q3-5d dosing.
Terminal elimination half-life is approximately 2 hours (range 1.1–2.5 h) for trioxsalen after oral administration; clinical phototoxic effect peaks at 2–4 hours post-dose.
Primarily renal: 90-95% as metabolites within 24 hours; minimal biliary/fecal (<5%).
Primarily renal elimination of metabolites; less than 5% excreted unchanged in urine. Approximately 90% of a radiolabeled dose is recovered in urine within 24 hours, with less than 5% in feces.
Category C
Category C
Psoralen
Psoralen